Users of Truvada, Viread, Atripla, Stribild, and Complera:

Kidney and bone damage linked to HIV drugs.

If you or a loved one has taken Truvada, Viread, Atripla, Stribild, or Complera and experienced kidney and/or bone damage, such as:

• acute kidney or renal failure,
• chronic kidney disease,
• related kidney injuries,
• osteoporosis (brittle bone/weakened bone),
• osteopenia (loss of bone density),
• osteomalacia (softening of the bone),
• bone fractures,
• and related orthopedic injuries.

you may be eligible for compensation.

A recent lawsuit states that the manufacturer was aware of the possible risks of its TDF (tenofovir disoproxil fumarate) drugs, but delayed the release of a less-toxic drug, in order to increase profit.

In October 2001 the federal Food and Drug Administration approved tenofovir disoproxil fumarate, TDF, a formulation of an intravenous drug that could be taken orally to prevent HIV. The manufacturer, Gilead Sciences, purchased the original drug and created an oral formulation, marketing it under the names Truvada, Viread, Atripla, Stribild, and Complera. To ensure the efficacy of the drug, the required oral dosage was high, causing damaging side effects to patients’ kidneys and bones.

By 2004 the scientists at Gilead had developed and tested a safer HIV drug, TAF (tenofovir alafenamide fumarate). The recent lawsuit claims that Gilead shelved TAF until the patent on TDF expired.